European Psychiatry - Volume 41 - April 2017

180 / 916

S176 25th European Congress of Psychiatry / European Psychiatry 41S (2017) S170–S237
Health care should be improved to provide better response to this
type of patients.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0205
Effects of smartphone-based memory
training for older adults with
subjective memory complaints
M.S. Shin ∗ Oh eo . Lee J. Song
1 Seoul National University College of Medicine, Department of
Psychiatry and Behavioral Science, Seoul, Republic of Korea
2 Seoul National University College of Medicine, Department of
Clinical Medical Sciences, Seoul, Republic of Korea
3 Seoul National University Hospital, Department of Neuropsychiatry,
Seoul, Republic of Korea
∗ Corresponding author.
Introduction Brain health has garnered increasing attention as a
requisite condition for healthy aging. The rapid growth in mobile
health and increasing smartphone ownership among older adults
has paved the way for smartphones to be utilized as effective tools
for improving mental fitness.
Objectives There are few studies that have explored the efficacy
of smartphone-based cognitive training. The present study exam-
ined the memory-enhancing effects of smartphone-based memory
training for older adults.
Aims We explored whether newly developed application
“Smartphone-based brain Anti-aging and memory Reinforcement
Training (SMART)” improved memory performance in older adults
with subjective memory complaints.
Methods A total of 53 adults (mean age: 59.3 years) were ran-
domised into either one of two smartphone-based intervention
groups (SMART vs. Fit Brains®) or a wait-list group. Participants
in the intervention groups underwent 15–20minutes of training
per day, five days per week for 8weeks. We used objective cogni-
tive measures to evaluate changes with respect to four domains:
attention, memory, working memory (WM), and executive func-
tion (inhibition, fluency, etc.). In addition, we included self-report
questionnaires to assess levels of subjective memory complaints.
Results The performance on WM test increased significantly in
the SMART group (t[17] = 6.27, P < 0.0001) but not in the control
groups. Self-reports of memory contentment, however, increased
in the Fit Brains® group only (t[18] = 2.12, P = 0.048).
Conclusions Use of an 8-week smartphone-based memory train-
ing program may improve working memory function in older
adults. However, objective improvement in performance does not
necessarily lead to decreased subjective memory complaints.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0206
Drug–drug interactions between
antibiotics and
psychopharmaceuticals in Slovenian
nursing homes: A retrospective
observational cohort study from a
national perspective
M. Stuhec ∗, P. Ines , D. Stepan , U. Lea , M. Petek Ster ,
B. Beovi´c
1 Faculty of Pharmacy, Biopharmacy and Pharmacokinetics,
Ljubljana, Slovenia
2 Faculty of Pharmacy Ljubljana, Biopharmacy and Pharmacokinetics,
Ljubljana, Slovenia
3 Faculty of Medicine Ljubljana, Department of Family Medicine,
Ljubljana, Slovenia
4 Faculty of Medicine Ljubljana, Department of Infectious Diseases,
Ljubljana, Slovenia
∗ Corresponding author.
Background Drug–drug interactions (DDIs) between antibiotics
and psychopharmaceuticals in large national data have not been
described yet.
Objectives In most European countries, there is no national data
on DDIs in patients within nursing homes.
Aim To present themost important DDIs in the Slovenian nursing
homes to avoid serious DDIs in the future.
Methods A retrospective study was carried in 2015 and with 233
patient on antibiotic treatment. All study data from the patients’
records were obtained from the patients’ charts. DDIs were deter-
mined by different interaction classeswith LexicompOnlineTM 19.0
version and only X (major interactions) and D (minor interactions)
were included.
Results A total of 233 patients (age = 83.5, SD = 9.8) were treated
with antibiotics (only 2without psychopharmaceuticals). The num-
ber of patients with at least 1 interaction was: 72 (30.9%) for X and
172 (73.8%) for D and the average number of medication/patient
was 10.9 (SD = 3.9). Twenty-seven patients (11.5%) were treated
with at least 1 X DDIs s (17 patients ciprofloxacin, 6 moxifloxacin,
3 azithromycin and 1 levofloxacin). Quetiapine and ciprofloxacin
was most frequent DDIs occured in 12 patients. Twenty-seven
DDIs were pharmacodynamic (QTc prolongation) and 3 pharma-
cokinetic (ciprofloxacin-tizanidine, ciprofloxacin and duloxetine in
2 patients; n = 3). Quetiapine was most frequent prescribed psy-
chopharmaceutical in X DDIs.
Conclusions DDIs between these two groups are seen very often.
If an antidepressant should be used in these patients, we recom-
mend sertraline instead of escitalopram and venlafaxine instead of
duloxetine and mirtazapine instead of quetiapine. We also recom-
mend a use of penicilins instead of ciprofloxacin and azithromycin.
Disclosure of interest The authors have not supplied their decla-
ration of competing interest.
EW0207
Efficacy of rivastigmine on loss of
appetite in patients with Alzheimer’s
disease
N. Tsuno∗, T. Mori , Y. Nakamura
Kagawa University, Department of Neuropsychiatry, Miki-cho,
Kita-gun, Japan
∗ Corresponding author.
Introduction It has been said that nearly 30% of the patients with
Alzheimer’ disease (AD) manifest loss of appetite, which might
increase cognitive impairments and the incidence of neuropsy-
chiatric symptoms, and malnutrition. As a result, a vicious cycle
decreases functionality and quality of life in patients with AD.
Cholinesterase inhibitors (ChEIs) is the first-line drugs in the treat-
ment of AD. On the one hand, appetite or weight loss can be seen
due to gastrointestinal side effects in the treatment of ChEIs. On the
other hand, there are some reports in clinical-settings that patients
with AD treated with rivastigmine transdermal patch showed the
improvement of appetite loss.
Objectives To evaluate the efficacy of rivastigmine transdermal
patch in AD patients with poor appetite.
Methods In this 16-weeks, multicenter prospective study,
patients with mild to moderate AD, who manifest loss of appetite
and began to receive rivastigmine transdermal patch therapy, were
enrolled. The amount of food, total time-eating, body weight, Mini
Mental State Examination (MMSE) and Neuropsychiatric Inventory
(NPI) were evaluated.